Elevance Health, Inc. (NYSE:ELV) Receives Consensus Rating of “Moderate Buy” from Analysts

Elevance Health, Inc. (NYSE:ELV) has earned an average rating of “Moderate Buy” from the twenty-one analysts that are covering the firm, MarketBeat Ratings reports. Nine equities research analysts have rated the stock with a hold recommendation and twelve have assigned a buy recommendation to the company. The average 1 year price objective among brokers that have covered the stock in the last year is $399.6316.

Several research firms have recently weighed in on ELV. Sanford C. Bernstein reissued an “outperform” rating and issued a $431.00 target price on shares of Elevance Health in a research report on Tuesday, January 6th. Barclays boosted their price objective on Elevance Health from $385.00 to $404.00 and gave the company an “overweight” rating in a report on Monday, January 5th. Morgan Stanley reduced their target price on Elevance Health from $359.00 to $352.00 and set an “equal weight” rating on the stock in a report on Wednesday, December 17th. JPMorgan Chase & Co. boosted their price target on Elevance Health from $384.00 to $394.00 and gave the company an “overweight” rating in a report on Tuesday, October 28th. Finally, Bank of America raised their price objective on Elevance Health from $330.00 to $370.00 and gave the stock a “neutral” rating in a research note on Friday, October 10th.

Elevance Health Price Performance

Shares of NYSE ELV opened at $342.01 on Thursday. The company has a quick ratio of 1.56, a current ratio of 1.56 and a debt-to-equity ratio of 0.71. Elevance Health has a fifty-two week low of $273.71 and a fifty-two week high of $458.75. The business has a 50 day moving average price of $350.56 and a two-hundred day moving average price of $328.87. The firm has a market cap of $76.01 billion, a PE ratio of 13.98, a price-to-earnings-growth ratio of 1.66 and a beta of 0.51.

Elevance Health (NYSE:ELV) last released its earnings results on Wednesday, January 28th. The company reported $3.33 EPS for the quarter, beating the consensus estimate of $3.10 by $0.23. The company had revenue of $49.31 billion during the quarter, compared to analysts’ expectations of $49.52 billion. Elevance Health had a return on equity of 16.17% and a net margin of 2.84%.The business’s revenue was up 9.6% on a year-over-year basis. During the same period in the prior year, the business posted $3.84 EPS. Elevance Health has set its FY 2026 guidance at 25.500- EPS. Sell-side analysts expect that Elevance Health will post 33.96 earnings per share for the current fiscal year.

Elevance Health Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, March 25th. Investors of record on Tuesday, March 10th will be given a dividend of $1.72 per share. The ex-dividend date of this dividend is Tuesday, March 10th. This represents a $6.88 dividend on an annualized basis and a dividend yield of 2.0%. This is a boost from Elevance Health’s previous quarterly dividend of $1.71. Elevance Health’s payout ratio is currently 27.96%.

Elevance Health News Roundup

Here are the key news stories impacting Elevance Health this week:

• Positive Sentiment: Q4 EPS beat consensus ($3.33 vs. $3.10) and management cited rising premiums plus a surge in Carelon revenues — a key reason investors see continued earnings resilience. Elevance Health Q4 Earnings Beat
• Positive Sentiment: Board raised the quarterly dividend to $1.72 (annualized yield ~2.0%), a modest increase from $1.71 — supportive for income-focused shareholders and signals confidence in cash flow.
• Neutral Sentiment: Revenue grew ~9.6% YoY to $49.31B but came in slightly below consensus; net margin and ROE remain modest, so growth is present but profit dynamics are mixed. Press Release / Slide Deck
• Negative Sentiment: FY‑2026 EPS guidance was lowered to about 25.50, below the Street (~26.89); management warned medical costs will remain elevated, which is a direct near‑term headwind to margins and valuation. Elevance forecasts 2026 profit below estimates
• Negative Sentiment: Market commentary highlights Medicare Advantage and reimbursement/membership pressures as reasons for selloff and heightened volatility in ELV shares following the earnings release. Barron’s: Earnings adding to Medicare pain

Hedge Funds Weigh In On Elevance Health

Institutional investors have recently made changes to their positions in the stock. Nilsine Partners LLC lifted its stake in shares of Elevance Health by 1.5% in the third quarter. Nilsine Partners LLC now owns 1,918 shares of the company’s stock worth $620,000 after buying an additional 29 shares in the last quarter. Sound View Wealth Advisors Group LLC raised its holdings in Elevance Health by 3.0% in the 4th quarter. Sound View Wealth Advisors Group LLC now owns 1,011 shares of the company’s stock valued at $354,000 after acquiring an additional 29 shares during the last quarter. Perigon Wealth Management LLC lifted its stake in Elevance Health by 2.2% in the 4th quarter. Perigon Wealth Management LLC now owns 1,371 shares of the company’s stock worth $481,000 after purchasing an additional 29 shares in the last quarter. Fulton Breakefield Broenniman LLC boosted its holdings in shares of Elevance Health by 3.6% during the 4th quarter. Fulton Breakefield Broenniman LLC now owns 825 shares of the company’s stock worth $289,000 after purchasing an additional 29 shares during the last quarter. Finally, Savvy Advisors Inc. grew its position in shares of Elevance Health by 3.2% in the fourth quarter. Savvy Advisors Inc. now owns 979 shares of the company’s stock valued at $343,000 after purchasing an additional 30 shares in the last quarter. 89.24% of the stock is owned by institutional investors.

About Elevance Health

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.